Figure 7. Effects of TRPV4 antagonist on the cardiac expression of activated RISK (P-Akt, P-ERK, P-GSK-3β) and SAFE (P-STAT3) pathways at 4 h after myocardial I/R in mice.

The TRPV4 antagonist HC-067047 (10 mg/Kg) was intraperitoneally injected at 1 h after reperfusion. Representative Western blot images are shown in A, quantification in B. n = 6/group, ^P < 0.05, ^^^P < 0.001 vs sham, ***P < 0.01 vs vehicle. Full-length blots/gels are presented in Supplementary Figs 8–11.